Get the Stockscreener App
1.22
2.40%
-0.03
After Hours:
1.24
0.02
+1.64%
Pacific Biosciences Of California Inc stock is traded at $1.22, with a volume of 4.62M.
It is down -2.40% in the last 24 hours and down -28.65% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
See More
Previous Close:
$1.25
Open:
$1.235
24h Volume:
4.62M
Relative Volume:
0.78
Market Cap:
$378.93M
Revenue:
$160.03M
Net Income/Loss:
$-128.58M
P/E Ratio:
-2.8585
EPS:
-0.4268
Net Cash Flow:
$-121.21M
1W Performance:
+8.93%
1M Performance:
-28.65%
6M Performance:
-45.05%
1Y Performance:
+29.58%
1-Day Range:
$1.205
$1.285
1-Week Range:
$1.09
$1.285
52-Week Range:
$0.8511
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.22 | 388.25M | 160.03M | -128.58M | -121.21M | -0.4268 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Pacific Biosciences: Pressure Is Rising (NASDAQ:PACB) - Seeking Alpha
PACB (Pacific Biosciences of California) ROC % : -47.66% (As of Mar. 2026) - GuruFocus
Q4 2025 Pacific Biosciences of California Inc Earnings Call Transcript - GuruFocus
PACB Stock Price, Quote & Chart | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill
PacBio to Participate in the Jefferies Global Healthcare Conference - Yahoo Finance
Here's why you should add PacBio stock to your portfolio now - MSN
Pacific Biosciences of California (PACB) Stock Price, News & Analysis - MarketBeat
Pacific Biosciences of California sets $300 price point for 20x human genome sequencing on Revio - Traders Union
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology - Yahoo Finance
PACB Secures $7.2M in Seed Funding and Partners with Blank Bio - GuruFocus
PacBio wins Basecamp Research deal for Trillion Gene Atlas initiative - MSN
Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology - BioSpace
AI lab Blank Bio raises $7.2M, teams with PacBio on tumor RNA - Stock Titan
PacBio tumbles after narrowing full-year revenue guidance - MSN
Sequencing constraints lifted as Pacific Biosciences of California enables combined genetic and methylation detection - Traders Union
PacBio expects $165M-$175M 2026 revenue as SPRQ-Nx ships later this month - MSN
Pacific Biosciences of California introduces HiFi Starter Kit to expand long-read sequencing access - Traders Union
Pacific Biosciences stock (US6932471010): Latest developments and market position - AD HOC NEWS
PACB SEC FilingsPacific Biosc 10-K, 10-Q, 8-K Forms - Stock Titan
PACB Technical Analysis | Trend, Signals & Chart Patterns | PACIFIC BIOSCIENCES OF CALIF (NASDAQ:PACB) - ChartMill
PacBio (PACB) Q1 earnings report preview: What to look for - MSN
Pacific Biosciences (PACB) Reports Q1 EPS - Insider Monkey
Pacific Biosciences of California brings global researchers together in Fukuoka - Traders Union
Why PacBio (PACB) Shares Are Getting Obliterated Today - Yahoo Finance
5 Best Penny Stocks to Buy Before They Explode - Insider Monkey
PACB Q1 Deep Dive: Consumables Growth and Clinical Adoption Offset Instrument Weakness - Yahoo Finance
Pacific Biosciences of California launches PacBioPRISM tour finale in Japan to drive HiFi innovation - Traders Union
Pacific Biosciences of California, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:PACB) 2026-05-11 - Seeking Alpha
PACB Maintained by Barclays -- Price Target Raised to $1.50 - GuruFocus
TradingKey - TradingKey
Long-read genome scan spots key variants in unexplained subfertility - Stock Titan
HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss - Sahm
PacBio (PACB) Q1 2026 Earnings Call Transcript - AOL.com
Pacific Biosciences Of California (PACB) Q4 Loss Highlights Ongoing Break From Bullish Profitability Narratives - Sahm
Pacific Biosciences of California, Inc. Q1 2026 Financial Results and SEC 10-Q Filing Highlights - Minichart
[10-Q] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Quarterly Earnings Report - Stock Titan
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 1Q 2026: Revenue $37.18M, EPS ($0.03) — 10-Q Summary - TradingView
Pacific Biosciences stock (US6932471010): Flat Q1 revenue amid funding pressure in U.S. research sec - AD HOC NEWS
Pacific Biosciences (PACB) Shares Drop Following Q1 Revenue Miss - GuruFocus
Pacific Biosciences Shares Fall Amid 1Q Revenue Pressures - Moomoo
Pacific Biosciences of California, Inc. (PACB) Stock Rises on Q1 2026 Earnings - Moomoo
PACB Q1 Earnings Beat, Revenues Miss Estimates, Gross Margin Down - TradingView
Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2 - Moomoo
CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):